124 research outputs found
Progressive visceral leishmaniasis misdiagnosed as cirrhosis of the liver: a case report
<p>Abstract</p> <p>Introduction</p> <p>Visceral leishmaniasis is a potentially life-threatening infectious disease which is caused by parasites of the genus <it>Leishmania</it> and characterized in most cases by the presence of fever as well as signs and symptoms similar to those found in liver cirrhosis.</p> <p>Case presentation</p> <p>In this case report we describe the history of a 50-year-old Caucasian man incorrectly diagnosed as having hepatitis C virus-associated liver cirrhosis, with a massive weight loss of around 100 kg during the previous 2 years. However, suspecting a lymphoproliferative disorder, we were able to make a correct diagnosis of visceral leishmaniasis by bone marrow examination. After a course of therapy with Liposomal Amphotericin-B the patient recovered and now, 20 months post-treatment, he is well and has regained a good part of the lost weight.</p> <p>Conclusions</p> <p>This case taught us that patients with massive splenomegaly, even with a diagnosis of liver cirrhosis, should be investigated for infectious or lymphoproliferative diseases.</p
GRP78 POLYMORPHISM rs430397 IS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN A SOUTHERN ITALIAN POPULATION
Clinical course and management of acute and chronic viral hepatitis during pregnancy.
Pregnancy is a para-physiologic condition, which usually evolves without any complications in the majority of women, even if in some circumstances moderate or severe clinical problems can also occur. Among complications occurring during the second and the third trimester very important are those considered as concurrent to pregnancy such as hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, HELLP syndrome and acute fatty liver of pregnancy. The liver diseases concurrent to pregnancy typically occur at specific times during the gestation and they may lead to significant maternal and foetal morbidity and mortality. Commonly, delivery of the foetus, even preterm, usually terminates the progression of these disorders. All chronic liver diseases, such as chronic viral hepatitis, autoimmune hepatitis, Wilson's disease, and cirrhosis of different aetiologies may cause liver damage, independently from pregnancy. In this review we will also comment the clinical implications of pregnancies occurring in women who received a orthotopic liver transplantation (OLT) Therefore, the management of immunosuppressive therapy before and after the delivery in women who received liver transplant is becoming a relevant clinical issue. Finally, we will focus on acute and chronic viral hepatitis occurring during pregnancy, on management of advanced liver disease and we will review the literature on the challenging issue regarding pregnancy and OLT
ALLELIC VARIANTS OF CYP2E1 GENE IN HEPATOCARCINOMA PATIENTS AND IN HEPATIC TUMOR CELL LINES
Background and Aims: Hepatic enzyme CYP2E1 is involved in the
metabolism of a number of exogenous and endogenous substances
(i.e. ethanol, drugs and chemical carcinogens). Being polymorphic,
CYP2E1 gene can give different xeno-metabolic capabilities in a
population and it is well known that inadequate or no enzymatic
deactivation of xenobiotics could induce an increased susceptibility
to disease and cancer. In particular, one of the 5 -flanking region
polymorphisms, able to differentiate CYP2E1 gene transcriptional
activity, is caused by the appearance/disappearance of RsaI and
PstI restriction sites, which generates two different alleles, namely
*C1(Rsa+/Pst−) and *C2(Rsa−/Pst+) respectively, reported to be in
complete linkage disequilibrium.
Methods: To confirm the existence of a correlation between some
particular CYP2E1 genotypes/haplotypes and hepatocarcinoma, we
determined CYP2E1 PstI/RsaI genotypes/haplotypes by RFLP-PCR in
a cohort of central western Sicily hepatocarcinoma patients and in
a population of healthy students from the same geographic area.
Results: In hepatocarcinoma patients, modal genotype association
was Rsa++/Pst−−, corresponding to CYP2E1 *C1/*C1 haplotype,
whereas the Rsa+−/Pst−+ association, equivalent to CYP2E1 *C1/*C2
haplotype, resulted to have the lowest frequency both in patients
and in controls. Moreover, both in patients and in controls, noncanonical
genotype associations were frequent and arose from
a no-linkage disequilibrium between the two polymorphic sites.
Other authors reported this finding as a rare occurrence. Thus,
from analysis of only one restriction site, Rsa++ genotype was
approximately 1.5-fold more frequent in patients than in controls,
and the non-canonical Rsa+− genotype was found relatively
frequent in patients. Moreover, HuH7 and HA22T transformed
hepatocarcinoma cell lines also showed the Rsa+− genotype.
Conclusions: These results suggest that the presence in CYP2E1
genotype of at least one allele with an Rsa I restriction site is
correlated with hepatocarcinoma. As this site is known a consensus
sequence for some specific CYP gene transcription factors, like
HNF-1, it may be supposed that a single nucleotide polymorphism
can alter the possibility of HNF-1 to bind CYP2E1 promoter. This
could determine a marked change in the transcriptional activity
of the gene, incompetence in xenobiotic metabolism or in toxic
substance deactivation and an increased susceptibility to neoplastic
diseases, such as hepatocarcinoma
long term follow up of hepatitis c virus positive patients with persistently normal serum transaminases
Material and methods. This study prospectively evaluated the progression of liver disease in a group of anti-HCV-positive patients with persistently normal ALT levels (PNALT) who were HCV-RNA positive. Patients selected for this study were those who presented with PNALT according to the Italian Association for the Study of the Liver (AISF) criteria in the year 1995/96 and underwent liver biopsy. They were divided into two groups according to their ALT evolution. Forty-five patients were included in this study. Results. After a median follow-up time of 180 months twenty-five of them maintained PNALT, but two of these developed liver cirrhosis (LC) in a mean time of 174 and 202 months, respectively. Twenty patients had flares of ALT and three of them developed LC in a mean time of 162-178 months. Twelve of these patients underwent current antiviral treatment; six patients were SVR. At baseline, the 5 patients who progressed to LC had age and BMI significantly higher than patients without LC (P < 0.005 and P < 0.01, respectively). Grading (P < 0.006) and staging (P < 0.003) were also more severe at histology, while serum HDL-C levels were statistically lower (P < 0.002). Comparing patients with flares of transaminases with and without LC, we found a significant difference at baseline for age, BMI, HDL-C, grading and staging (P < 0.05; P < 0.01 and P < 0.003, respectively). Conclusion. In HCV-RNA positive patients associated with PNALT the grade of disease activity increased over the years in only half of patients and a higher degree of liver fibrosis at baseline was the major relevant factor for progression
Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection
SummaryBackgroundLimited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk.MethodsFifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovascular disease risk was evaluated using the 10-year Framingham risk score.ResultsHS prevalence in the whole HIV population was 53% (54% in mono-infected patients and 51% in co-infected patients). HS was associated with lipodystrophy and triglyceride values (p1 year (p<0.01). By multivariate analysis, only triglyceride levels (p<0.02) and Framingham risk score (p<0.05) were independently associated with HS in both HIV groups. No correlation was observed between HS and advanced liver fibrosis, measured by transient elastography.ConclusionsHS was common in HIV patients, occurring in about half of the population. HS was found to be linked with the Framingham risk score, but was not correlated with advanced liver fibrosis. We suggest that in our HIV population with HS, the burden of cardiovascular disease risk is greater than that of liver disease progression
Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases
Aim/Objective/Background
Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used. Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported. Here, we report two new cases of rivaroxaban-induced hepatitis.
Methods
A systematic search of case reports on the MEDLINE database encompassing the years 2008–2016 was carried out.Additional references were obtained following a manual search of the retrieved papers. We report two new cases of adverse events occurred in patients treated with rivaroxaban (20 mg/die) to prevent systemic embolism, who presented with hepatocellular liver injury with onset at 8 weeks after initiation of the drug intake.
Results
Twenty-six cases were retrieved from MEDLINE (57.7% female, 42.3% male). Using the Roussel Uclaf Causality Assessment Method (RUCAM) scale, liver injury was classified as hepatocellular (42.3%), cholestatic (26.9%), or mixed (15.4%). Older age (≥65 years) was present as a risk factor in 57.7%. The time lapse between initiation of treatment and onset of hepatic injury ranged from 2 to 180 days (median: 15 days). Our two new patients were diagnosed with drug-induced liver injury (hepatocellular pattern) using the ‘consensus criteria’, for drug-induced liver injury. Their RUCAM scores were calculated and assessed as highly probable and probable, respectively. A clinical recovery after rivaroxaban withdrawal was observed.
Conclusion
Direct-acting oral anticoagulants have been commonly prescribed, even if safety issues regarding the use of these drugs are still an ongoing concern, especially in patients experiencing chronic liver disease. Dedicated postauthorization safety studies should be undertaken to better define rivaroxaban-induced drug-induced liver injury
Vitamin D and Osteoporosis in HIV/HCV Coinfected Patients: A Literature Review
Vitamin D deficiency further increases the risk of osteoporosis in HIV-positive patients coinfected with hepatitis C virus (HCV); however, it is still unclear whether HCV-related increased fracture risk is a function of the severity of liver disease. The aim of this review was to identify studies on associative vitamin D deficiency patterns in high-risk populations such as HIV/HCV coinfected patients. We did this by searching MEDLINE and EMBASE databases, from inception to August 2014, and included bibliographies. The final 12 articles selected are homogeneous in terms of age but heterogeneous in terms of sample size, participant recruitment, and data source. Most of the HIV/HCV coinfected patients have less than adequate levels of vitamin D. After reviewing the selected articles, we concluded that vitamin D deficiency should be regarded as a continuum and that the lower limit of the ideal range is debatable. We found that vitamin D deficiency might influence liver disease progression in HIV/HCV coinfected patients. Methodological issues in evaluating vitamin D supplementation as a relatively inexpensive therapeutic option are discussed, as well as the need for future research, above all on its role in reducing the risk of HCV-related fracture by modifying liver fibrosis progression
Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected mediterranean subjects
- …